Jessica Brennan
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 21 years
- Graduated 2005
Offices
1 location · University of California San Francisco · 1,780 clinicians in this group
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Jessica Brennan’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G15126 · Cancelled
Licence status: Cancelled · since 1968 · University of Wisconsin Medical School.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$7,339
Pharmacies billed $7,339 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 25) in 2024. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
25 generic and 0 brand-name prescriptions · $7,339 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 25 | None | 0% (0) | 0% | $7,339 |
| 2023 | 37 | None | 0% (0) | None | $7,669 |
| 2022 | 41 | None | 0% (0) | None | $4,677 |
| 2021 | 15 | None | 0% (0) | 0% | $817 |
| 2020 | 28 | None | 0% (0) | None | $16,362 |
| 2019 | 42 | None | 0% (0) | None | $17,830 |
| 2018 | 79 | None | 0% (0) | 0% | $1,976 |
| 2017 | 82 | None | 0% (0) | None | $18,134 |
| 2016 | 110 | None | 0% (0) | None | $11,746 |
| 2015 | 111 | None | None | None | $11,360 |
| 2014 | 109 | 13 | None | None | $14,886 |
| 2013 | 193 | 17 | 0% (0) | None | $33,854 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 1 drug
| Omeprazole | 11 | $79 | $7 |
2020: 1 drug
| Tacrolimus | 11 | $4,546 | $413 |
2018: 5 drugs
| Mycophenolate Mofetil | 12 | $990 | $82 |
| Guanfacine | 12 | $247 | $21 |
| Bupropion | 12 | $212 | $18 |
| Amlodipine Besylate | 13 | $124 | $10 |
| Prednisone | 12 | $75 | $6 |
2017: 2 drugs
| Sirolimus | 14 | $6,654 | $475 |
| Amlodipine Besylate | 11 | $97 | $9 |
2016: 2 drugs
| Tacrolimus | 11 | $910 | $83 |
| Amlodipine Besylate | 20 | $51 | $3 |
2015: 3 drugs
| Cyproheptadine | 11 | $443 | $40 |
| Fludrocortisone Acetate | 15 | $245 | $16 |
| Amlodipine Besylate | 16 | $161 | $10 |
2014: 2 drugs
| Tacrolimus | 16 | $5,342 | $334 |
| Fludrocortisone Acetate | 15 | $456 | $30 |
2013: 5 drugs
| Tacrolimus | 14 | $7,538 | $538 |
| Omeprazole | 34 | $447 | $13 |
| Fludrocortisone Acetate | 14 | $408 | $29 |
| Amlodipine Besylate | 19 | $276 | $15 |
| Prednisone | 14 | $135 | $10 |
Money from drug and device companies
$246 in 2025
| 2025 | 3 | 3 | None | $246 |
| 2024 | 1 | 1 | None | $6 |
| 2023 | 1 | 1 | None | $105 |
| 2022 | 1 | 1 | None | $52 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medline Industries LP | None | $205 | 1 payment
|
| Novo Nordisk | None | $22 | 1 payment
|
| Apellis Pharmaceuticals | None | $19 | 1 payment
|
See all 3 published payments
| Medline Industries LP | Meals · 2025-04-30 | None | $205 |
| Apellis Pharmaceuticals | Meals · 2025-04-02 | None | $19 |
| Novo Nordisk | Meals · 2025-02-18 | None | $22 |
See earlier years (2024, 2023, 2022)
2024: $6
| Kamada | Cytogam | $6 | 1 payment
|
2023: $105
| Alnylam Pharmaceuticals | Oxlumo | $105 | 1 payment
|
2022: $52
| Sanofi-Aventis U.S. | None | $52 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1225239684
- Licence
- CA 15126California G15126: Cancelled
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0200X (363LP0200X)
- Mailing address
- 119 Parker Ave, San Francisco, CA, 94118
- NPI first listed
- 2007-05-31
- NPI last updated
- 2012-03-13
This is when the NPI record was last certified, not a medical board exam.